An agonist of TLR7 with immune response modifying activity; Approved for basal cell carcinoma; In Phase III for VIN and CIN; Imiquimod\\\'s proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells
Congratulations! This product is added successfully!